Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CT
Cytosorbents Corp.
CTSO
Mkt Cap
$12.8M
Volume
598.24K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CT
CTSO
CT
Cytosorbents Corp.
CTSO
News
·
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
Mkt Cap
$13.0M
Volume
598.24K
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
CytoSorbents reported a 3% decrease in Q1 2025 revenue, but improved operating loss and net loss. The company is making progress with its DrugSorb-ATR device, which is under review by the FDA and Health Canada.
Benzinga · May 14, 2025
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in CABG patients on the antiplatelet drug Brilinta. The company plans to continue working with the FDA to resolve the remaining issues and obtain regulatory approval.
Benzinga · May 1, 2025
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth
CytoSorbents reported strong Q4 2024 preliminary results, with product revenue growth of 22-25% and gross margin improvement to 70%. However, the company's shares dipped despite the positive outlook, as it prepares to enter the North American market with its DrugSorb-ATR product pending regulatory approvals.
Benzinga · Jan 3, 2025
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
CytoSorbents Corporation reported strong preliminary Q4 2024 financial results, with product revenue growth estimated at 22-25% year-over-year and gross margin improving to around 70%. The company also provided updates on its regulatory progress for DrugSorb-ATR, an investigational device to reduce perioperative bleeding in CABG surgery patients.
GlobeNewswire Inc. · Jan 3, 2025
Why CytoSorbents (CTSO) Stock Is Trading Higher - CytoSorbents (NASDAQ:CTSO) - Benzinga
CytoSorbents shares are trading 21% higher after the company entered into a new $20 million credit facility with Avenue Capital Group to support its CytoSorb® franchise and aid in FDA and Health Canada applications for DrugSorb™-ATR.
Benzinga · Jul 2, 2024
CytoSorbents Secures $20 Million Credit Facility
$20 million credit facility provides CytoSorbents with important non-dilutive capital to support its regulatory and commercialization objectives
GlobeNewswire Inc. · Jul 2, 2024
CytoSorbents 公司宣布 CytoSorb® 獲得台灣監管部門批准
當地是全球最先進的醫療保健系統之一,現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術,用於治療危疾和心臟手術患者 當地是全球最先進的醫療保健系統之一,現在引進這個迄今應用於 75 個國家近 25 萬次治療的強大的血液淨化技術,用於治療危疾和心臟手術患者
GlobeNewswire Inc. · Jun 25, 2024
CytoSorbents Reports First Quarter 2024 Results
CytoSorbents Reports First Quarter 2024 Results
GlobeNewswire Inc. · May 9, 2024
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
GlobeNewswire Inc. · Apr 26, 2024
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
GlobeNewswire Inc. · Apr 17, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CT
CTSO
Cytosorbents Corp.
Buy
Sell
Market
Limit
Soon
CTSO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CTSO yet.
Related Tickers
Earnings